References
- Banov CH. The role of budesonide in adults and children with mild-to-moderate persistent asthma. J Asthma 2004;41:5–17
- Selroos O, Edsbäcker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma 2004;41:771–90
- Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998;101:457–63
- Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr 1998;132:976–82
- Kemp J, Wanderer AA, Ramsdell J, et al. Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma. Ann Allergy Asthma Immunol 1999;82:463–71
- Nelson HS, Bernstein IL, Fink J, et al., for the Pulmicort Turbuhaler Study Group. Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a doubleblind, placebo-controlled study in adults with moderate-to- severe chronic asthma. Chest 1998;113:1264–71
- McFadden ER, Casale TB, Edwards TB, et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol 1999;104:46–52
- Shapiro GG, Mendelson LM, Pearlman DS. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. Ann Allergy Asthma Immunol 2001;86:633–40
- National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full Report 2007. August 2007. NHLBI publication no. 08–4051
- Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute 2007: Available at: http://www.ginasthma.org
- Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005;127:335–71
- Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aersol Med 1994;7(Suppl 1) S43–7
- Fink JB. Metered-dose inhalers, dry powder inhalers, and transitions. Respir Care 2000;45:623–35
- Pulmicort Turbuhaler 200 μg [package insert]. Wilmington, DE: AstraZeneca LP, 2006
- Pulmicort Flexhaler 90 μg and 180 μg [package insert]. Wilmington, DE: AstraZeneca LP, 2006
- Kerwin EM, Pearlman DS, de Guia T, et al. Evaluation of efficacy, safety, and pharmacokinetics of budesonide delivered via two dry powder inhalers. Curr Med Res Opin 2008;4:1497–510
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225–44
- Borgström L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 2006;19:473–83